The Differential Diagnosis of Pseudobulbar Affect (PBA): Distinguishing PBA Among Disorders of Mood and Affect

  title={The Differential Diagnosis of Pseudobulbar Affect (PBA): Distinguishing PBA Among Disorders of Mood and Affect},
  author={David B. Arciniegas and Edward C. Lauterbach and David L. Ginsberg and Karen Anderson and Tiffany W. Chow and Laura A. Flashman and Robin A. Hurley and Daniel I. Kaufer and Thomas W. McAllister and Allison Reeve and R. Schiffer and Jonathan M. Silver},
  journal={CNS Spectrums},
  pages={1 - 16}
Abstract This monograph summarizes the proceedings of a roundtable meeting convened to discuss pseudobulbar affect (PBA). Two didactic lectures were presented, followed by a moderated discussion among 11 participants. Post-meeting manuscript development synthesized didactic- and discussion-based content and incorporated additional material from the neuroscience literature. A conceptual framework with which to distinguish between disorders of mood and affect is presented first, and disorders of… 

The epidemiology and pathophysiology of pseudobulbar affect and its association with neurodegeneration.

  • R. KingJ. Reiss
  • Psychology, Biology
    Degenerative neurological and neuromuscular disease
  • 2013
Pseudobulbar affect is a disorder resulting from neurologic damage manifesting as sudden, stereotyped affective outbursts that are not reflective of internal emotion, common in neurodegenerative disorders but poorly recognized.

Pseudobulbar Affect in Parkinsonian Disorders: A Review

Pseudobulbar affect (PBA) is a neurological symptom of inappropriate and uncontrollable laughter or crying that occurs secondary to a variety of neurological conditions, including parkinsonian

Diagnosing pseudobulbar affect in traumatic brain injury

This review presents the signs and symptoms of PBA in patients with existing TBI and outlines how to distinguish PBA from other similar conditions, and compares and contrasts the different diagnostic criteria found in the literature.

Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments

Dextromethorphan/quinidine, the first FDA-approved PBA medication, is a novel therapy with antiglutamatergic actions, and as life expectancy lengthens and neurologic settings of PBA become more common, the need for treatment can be expected to increase.

The causes and treatment of pseudobulbar affect in ischemic stroke

Antidepressants are probably the most attractive pharmacologic options for treating PBA and nonpharmacologic therapies have not been studied systematically, they should be explored in cognitively intact patients.

Pseudobulbar affect - A disabling but under-recognised consequence of neurological disease and brain injury

A combination of dextromethorphan hydrobromide and quinidine sulphate (DM/Q) has demonstrated significant efficacy in reducing PBA symptoms and a favourable safety profile in a series of clinical trials and in regular clinical use.

Revisiting the pathoanatomy of pseudobulbar affect: mechanisms beyond corticobulbar dysfunction

  • P. BedeE. Finegan
  • Psychology
    Amyotrophic lateral sclerosis & frontotemporal degeneration
  • 2018
Advanced neuroimaging techniques and well-characterized ALS cohorts offer a unique opportunity to clarify the contribution of specific neural circuits to the aetiology of PCL.

Pseudobulbar Affect Presenting as Aggressive Behavior

A 48-year-old man who presented with frequent episodes of sudden, frequent, uncontrollable laughing two years after his recurrent stroke is described and treated with dextromethorphan-quinidine, escitalopram, and divalproex, resulting in significant improvement in his mood and aggressive behavior.

Treatment of pseudobulbar affect in a mixed neurodegenerative disorder with compounded quinidine capsules and dextromethorphan cough syrup

An elderly woman admitted in our geriatric inpatient unit suffered from disturbing outbursts of crying and, less frequently, episodes of laughing. The patient was diagnosed with pseudobulbar affect



The neuropsychiatry of pathologic affect: an approach to evaluation and treatment.

A framework for the description, evaluation, and treatment of affective dysregulation is described, along with several specific methods that appear to be useful in the evaluation of patients with affective lability.

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine

Overall benefits of treatment are reflected in fewer episodes of crying and laughing and improvements in overall quality of life and quality of relationships.

Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients

Results were observed if patients were classified as PLC or non-PLC according to CNS-LS score]-17, suggesting that the CNS- LS is a valid measure for the assessment of PLC in MS patients and could be a useful instrument for clinical and research purposes.

Pseudobulbar crying induced by stimulation in the region of the subthalamic nucleus

Clinicians should be aware of this potential complication, the importance of differentiating it from stimulation induced depression, and its response to a serotonin reuptake inhibitor, such as sertraline.

Regulation of Affect.

  • Green
  • Psychology, Medicine
    Seminars in clinical neuropsychiatry
  • 1998
The neurobiological bases of pathological crying are discussed, and the multiplicity of pathological entities and lesion locations that can produce this pathological affect are highlighted.

[The effect of amitriptyline on the pathological crying and other pseudobulbar signs].

It is concluded that amitriptyline is an effective treatment of pathologic crying in ALS patients and that few mild and transient side effects were observed.

Palatal myoclonus: a reappraisal.

Poststroke depression and emotional incontinence

Development of PSD and PSEI is strongly influenced by lesion location, probably associated with the chemical neuroanatomy related to the frontal/temporal lobe–basal ganglia–ventral brainstem circuitry.

[Pathological laughing and crying].

The interpretation of affect incontinence as a disinhibitory phenomenon is supported by clinical and electromyographic observations, which found a lack of modulation of intensity in pathological laughter and crying.

Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis.

The point prevalence of pathological laughing and crying in multiple sclerosis was 10%, and it occurs in severely physically disabled patients, generally with long-standing disease.